强生公布最新研究数据,显示Tremfya®(古塞奇尤单抗)是唯一能够在肛周瘘管性克罗恩病患者中实现持续48周瘘管缓解的IL-23抑制剂。
强生公布最新研究数据,显示Tremfya®(古塞奇尤单抗)是唯一能够在肛周瘘管性克罗恩病患者中实现持续48周瘘管缓解的IL-23抑制剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.